Surrogate end points in heart failure (Q78032634)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11985901 AND SRC:MED&resulttype=core&format=json

10 December 2019

review article

1 reference

title

Surrogate end points in heart failure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11985901 AND SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

Inder S Anand

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11985901 AND SRC:MED&resulttype=core&format=json

10 December 2019

Viorel G Florea

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11985901 AND SRC:MED&resulttype=core&format=json

10 December 2019

Lloyd Fisher

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11985901 AND SRC:MED&resulttype=core&format=json

10 December 2019

language of work or name

English

0 references

publication date

1 May 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11985901 AND SRC:MED&resulttype=core&format=json

Journal of the American College of Cardiology

10 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11985901 AND SRC:MED&resulttype=core&format=json

10 December 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11985901 AND SRC:MED&resulttype=core&format=json

10 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11985901 AND SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

1414-1421

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11985901 AND SRC:MED&resulttype=core&format=json

Predictors of readmission among elderly survivors of admission with heart failure

10 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Early readmission of elderly patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Role of surrogate end points in the evaluation of drugs for heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Surrogates, semantics, and sensible public policy

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Use of the living with heart failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Surrogate endpoints in clinical trials: cardiovascular diseases.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Statistical validation of intermediate endpoints for chronic diseases

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Ventricular Premature Beats and Mortality after Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

QT dispersion and sudden unexpected death in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Autonomic nervous system and sudden cardiac death

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Neural Activity and Ventricular Fibrillation

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Can drug effects on mortality in heart failure be predicted by any surrogate measure?

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure?

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

The prognostic value of exercise capacity: a review of the literature

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Respiratory gas exchange in the assessment of patients with impaired ventricular function

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Functional capacity of patients with chronic left ventricular failure. Relationship of bicycle exercise performance to clinical and hemodynamic characterization.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines/prioritization

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

B-type natriuretic peptide in the diagnosis and management of congestive heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

B-type natriuretic peptide levels: a potential novel "white count" for congestive heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Factors influencing the one-year mortality of dilated cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Impact of left ventricular cavity size on survival in advanced heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study)

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Heart volume and cardiovascular mortality. A 16 year follow-up study of 1984 healthy middle-aged men

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Left ventricular volume in thrombolysed patients with acute anterior myocardial infarction: the effect of captopril and xamoterol

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016/S0735-1097(02)01773-4

7 January 2021

10.1016/S0735-1097(02)01773-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11985901 AND SRC:MED&resulttype=core&format=json

10 December 2019

1 reference